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facilities.
Rob Noel1, Yuki Abe2, Andrew Sinclair2
1Pall Life Sciences, 5 Harbourgate, Southampton Road, Portsmouth, UK
2Biopharm Services Ltd, Unit 1, Chess Business Park, Moor Road, Chesham
Abstract
For most biopharmaceutical manufacturers the cost, time and quality improvements offered by adopting
continuous manufacturing operations is, as with any new technology, inhibited by the research and
validation costs associated with early adoption. Additional effort is needed to validate the novel technology
in-house. There are simple changes that can be made in disposable biomanufacturing , which are
necessary for the eventual adoption of full continuous operations, and yet have benefits now. These step
changes are shown by economic & scheduling models to offer direct cost savings and improved facility
throughput. A road map of these step-wise improvements is provided that leads to fully continuous
processing, but minimises the technological risk.
The first step change is a wider adoption of process automation. Automation eliminates operator error,
reduces contamination risk and improves batch-batch quality. The higher direct cost of the operating
system is offset by improved utilisation of facilities and fewer batch failures.
The next step is to automate the operation of a combination of relatively simple units, such as dead-end
filtration, flow-through adsorption, virus filtration, in-line concentration. The aim is to minimise hold steps,
QC testing, processing time and maximise the use of disposable manifolds. Incorporating automated
integrity testing into the operation further enhances the processing. Examples of such operating systems
will be described, either as standard items that require configuration or as customised options, to illustrate
the economic risk/benefit analysis.
Additionally, the islands of continuous operation can be extended - for example, perfusion bioreactor
operation, capture chromatography integrated with low pH virus inactivation, or flowthrough polishing
chromatography integrated with virus filtration and diafiltration. Integrated chromatography and virus
inactivation will be reported with the main advantages seen from contracting the process from two working
shifts to one and yield increase when producing biotherapeutics sensitive to low pH or sensitive to changes
in pH through the isoelectric point.
How each step change compares to envisioned full continuous processing depends on the operating
requirements of the facility, with the key variables being the number of biopharmaceutical products
manufactured, number of batches per product, titre, bioreactor volume, changeover time and QA release
time. As with all facility and operational changes, the value of the benefits discussed depends on the
demand being placed on the facilities by products in clinical phases or commercial manufacturing.

